MICROB-PREDICT

YouTube video by concentris research management MICROB-PREDICT - Serum villin-1, a tell-tale sign of gut-barrier failure in cirrhosis (Dávid Tornai)

👉 In this video, Dávid Tornai (MD, PhD) from Maria Papp's group at the University of Debrecen in Hungary presents the consortium's research on serum #villin-1, a tell-tale sign of #GutBarrier failure in cirrhotic patients with acute #decompensation via a graphical abstract.

📽️ youtu.be/URerer6AxxY

Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation Serum villin-1 is a non-invasive indicator of gut barrier damage and short-term mortality in acutely decompensated cirrhosis. Incorporating villin-1 assessment into risk stratification methods improv...

👏 New study from Dávid Tornai and colleagues 🎉: Serum #Villin1 is a promising non-invasive marker of #GutBarrier damage in #cirrhosis and #ACLF.

It rises with severity, predicts 90-day mortality, links to #inflammation, and has been validated in an independent cohort!

📜 doi.org/10.1111/apt....

📽️ Now online 🎧: lnkd.in/dJuMmsc4
Watch or listen to the newest EASL Studio Episode on “Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance” from Wednesday, 26 Nov 2026.
#rifaximin #HepaticEncephalopathy #AntimicrobialResistance #cirrhosis #ACLF

EASL Campus Continue your hepatology and liver-related disease education though our multi-disciplinary, open access eLearning platform EASL Campus. Sign up to access state-of-the-art digital courses and resources...

The session will also be available to watch on demand on EASL Campus from Thursday, 27 November

👉 easlcampus.eu/easl-studio/...

Within MICROB-PREDICT, WP6 is uncovering the mechanisms by which rifaximin & albumin interact with the microbiome and the gut–liver axis, using cellular + rodent models.

On Wednesday, 26 Nov, at 6 pm CET, EASL Studio hosts a new episode titled “Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance”

The episode will be broadcast live on EASL.eu and can be accessed here:

📹 easl.eu/easl-studio-...

Don't miss it ☺️

🎉 Our new #mirobiome paper in #JHEP is out! We found distinct gut #virome shifts in #ACLF - from virulent to temperate #phages - with Lactococcus A + Enterococcus B phages linked to infections & higher 90-day mortality

👉 Read more: www.sciencedirect.com/science/arti...

📽️Video: youtu.be/0YF6qToBQUM

🌍 The MICROB-PREDICT team met in Münster, Germany from 1–2 October for its 14th Steering Committee Meeting!

👉 Team leaders discussed results from 20 new papers about late-stage #LiverDisease #cirrhosis #biomarkers and IPR topics as the project nears its final phase.

The finish line is in sight!

Secretory IgA Is a Key Marker Among Gut Barrier Dysfunction‐Related Immunoglobulins Predicting Outcomes in ACLF Background and Aims In cirrhosis, impaired gut mucosal immunity facilitates bacterial translocation (BT) instigating the proinflammatory cascade that exacerbates hepatic damage. The role of antibody...

🔬 Read the original publication by Boglarka Balogh, David Tornai, Aniko Csillag et al. (2025) on behalf of the MICROB-PREDICT consortium and the PREDICT study group of the EASL-CLIF consortium: onlinelibrary.wiley.com/doi/10.1111/...

🚨 New #LiverFailure insights 🚨

In patients with #cirrhosis + acute #decompensation, secretory #IgA strongly correlates with #gut-barrier failure and is a powerful predictor of 90-day mortality in acute-on-chronic #LiverFailure #ACLF

👉 Watch on YouTube: youtu.be/KapUqG7AFFk

#Biomarkers #GutBarrier

Both groups (placebo vs. #albumin treatment) are monitored closely regarding their liver disease & overall health. We thank the dedicated teams at all sites across Europe for their hard work in achieving this milestone. We look forward to continuing this progress toward completing the ALB-TRIAL! 💪

The ALB-TRIAL is a double-blinded, placebo-controlled clinical trial to see if a new biomarker can be used to predict which patients with #cirrhosis + #ascites benefit most from long-term human #albumin infusion. Moving towards personalised treatment, less complications & lower risk of death. 🔬⚕️🩺

👏 ALB-TRIAL hits 50% enrollment 🎉

Half of the planned 240 patients have now been recruited across 14 centres in 7 countries - great progress for the MICROB-PREDICT project!

Huge thanks to all site teams - Onward to full enrollment & better treatment for #cirrhosis patients with #ascites!
#albumin

Join this exciting event!

Don't miss our #OpenInnovation event, uniting experts in #DrugDevelopment, #bioinformatics, and #hepatology. Connect with researchers, industry professionals, and investors to share insights & explore collaboration opportunities!

🚀 Register now: inevent.uk/en/Crowdheli...

🧪 SAT-209 – #EASL2025
MNK6106 vs. rifaximin to treat #HepaticEncephalopathy - new Phase 2a data from Prof. @rajivjalan.bsky.social (UCL) explores safety, PK & ammonia-lowering potential. HE treatment innovation in motion! #Cirrhosis

🧠 SAT-210 – #EASL2025

New tool alert!

The #mHEST scale brings clarity to grading hepatic #encephalopathy in trials & clinics. A big step for #cirrhosis care. Kudos to Prof. @rajivjalan.bsky.social & his team!

#LiverHealth #HE #ClinicalResearch

🔬 Improving the prognostic performance of the #MELD score is a challenge that Nikolaj Torp (Odense University Hospital) took on, comparing the original score with MELD 3.0 in 777 patients with an acute #decompensation of #cirrhosis

#POSTER SAT-196-YI 👏

📅 Presented at #EASLCongress | #EASL2025

✨ #PosterTour today at #EASLCongress 2025:
All our 3 Horizon2020 #LiverResearch projects in 1 session!

Topic: #Cirrhosis & #PortalHypertension
Chair: Maria Papp

💡 Big moments:

#AMMON-OHE model for post-#TIPS #encephalopathy (Rajiv Jalan)

#Terlipressin response in AKI-HRS w/ CKD (Frank Uschner)

@easlnews.bsky.social

One last time #LIVE from the #EASLStudio: Tot Ziens Amsterdam, Hola Barcelona! 👋

As #EASL2025 draws to a close, Debbie Shawcross and Aleksander Krag reflect on the highlights from Amsterdam and set the stage for #EASL2026 in Barcelona.

Thank you for an inspiring #EASLCongress - see you next year!

🧪 Mads Israelsen (Odense Universitetshospital – Svendborg Sygehus) leads together with Alberto Zanetto the YI #Workshop on How to prepare a #Clinical #Practice #Guideline in Hepatology, offering valuable insights for young investigators.

📅 Presented at the #EASLCongress | #EASL2025

One last time at #EASL2025: Wim Laleman (KUL) hosts the EASL/CIRSE Skills Learning Centre session on #Liver #Haemodynamics, providing hands-on learning in liver disease management.

🕙 10:15 – 11:15, Skills Learning Centre 2
@easlnews.bsky.social @cirsesociety.bsky.social

Live from the #EASLCongress: Debbie Shawcross (KCL) presents on Rebooting immunity: Harnessing FMT to revive innate defences in #cirrhosis as part of the Symposium “Microbiome and liver health: Unveiling new therapeutic pathways” 🦠🧫

#EASL2025 @easlnews.bsky.social
@kingscollegelondon.bsky.social

Join us at the Industry Room: Evolving concepts in MASLD, ALD & MetALD at #EASLCongress

Learn about:
✏️ New terminology & pathophysiology
🔬Non-invasive tools for diagnosis, prognosis & monitoring

🚨 Stay updated on the latest in metabolic & alcohol-related liver disease!

#MASLD #MetALD

👏 What an accomplishment 🥳

Frederike Krus selected for this afternoon's #PosterTour at #EASLCongress

👉 POSTER ID FRI-175

Loss of hepatic #leptin clearance is associated with the development of #ACLF, acute-on-chronic #LiverFailure

📍 #Cirrhosis & Complications
📅 Fri, 9 May

@medblab.bsky.social

Prof. JonelTrebicka presents and discusses the development and success of #TIPS over the past 25 years, high above the rooftops of #Amsterdam.

We are ready for #EASLCongress. We are happy to welcome you at our Posters.

Breaking Barriers 🩺: Novel insights in today's evening Abstract Session on #Alcohol 🍷 at #EASLCongress (Alcohol-related #LiverDisease), co-chaired by Elisa Pose from MICROB-PREDICT partner Fundació Clínic per a la Recerca Biomèdica, FCRB, in Barcelona.

@easlnews.bsky.social
@europeliver.bsky.social

🩺 #POSTER FRI-226 by Wenyi Gu (@medblab.bsky.social at the Universitätsklinikum Münster #UKM) presents her newest results on the burden & impact of #extrahepatic organ failures in European patients with #cirrhosis.

📅 Presented at #EASLCongress | #EASL2025, up until 17h, still time to swing by ☺️

🌟 Rising star - first big conference for him, so give him an applause 👏!

Hendrik Rogge presents a great #poster today at #EASLCongress about the 📊 prediction of circulatory failure in intensive-care #patients with liver #cirrhosis & #ACLF.

👉 #POSTER FRI-182, up until 17h

@medblab.bsky.social

🔬 Maximilian Brol's #POSTER FRI-493

👉 Conversion from standard-release to prolonged-release tacrolimus mitigates #calcineurin-induced #nephrotoxicity in patients after #LiverTransplantation

The poster is still up until 17:00 today ☺️

📅 Presented at #EASLCongress 2025
@medblab.bsky.social